NCT04428814View on ClinicalTrials.gov

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

February 24, 2021

Study Completion Date

February 24, 2021

Conditions
Healthy Subjects
Interventions
BIOLOGICAL

CT-P43

45mg single dose

BIOLOGICAL

EU-approved Stelara

45mg single dose

BIOLOGICAL

US-licensed Stelara

45mg single dose

Trial Locations (2)

1010

Auckland Clinical Studies Limited, Grafton

8011

Christchurch Clinical Studies Trust Limited, Christchurch

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04428814 - Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects | Biotech Hunter | Biotech Hunter